Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexa B Schrock

Showing results (21-30 of 130) with videos related to

Pageof 13
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 30, 2023
Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinomaLaura Burns, Hanna Tukachinsky, Kira Raskina, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutationSamuel J Klempner, Kyle Gowen, Thomas K Lee, et al.
Head & Neck|December 23, 2016
Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literatureLauren M Thorpe, Alexa B Schrock, Rachel L Erlich, et al.
JCO Precision Oncology|October 31, 2022
APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine TherapySarah Sammons, Kira Raskina, Natalie Danziger, et al.
The Oncologist|October 4, 2019
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current EvidenceSamuel J Klempner, David Fabrizio, Shalmali Bane, et al.
Lung Cancer (Amsterdam, Netherlands)|January 10, 2025
Genomic analysis of comprehensive next generation sequencing data to explore the criteria for MET amplification as an actionable biomarker in NSCLCDavid Chun Cheong Tsui, Jessica K Lee, Candice Francheska B Tambaoan, et al.
The Oncologist|January 27, 2019
Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior TestingLise Boussemart, Annie Nelson, Michael Wong, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinibSai-Hong Ignatius Ou, Jean Cui, Alexa B Schrock, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2022
Quantifying the Value of Multigene Testing in Resected Early Stage Lung AdenocarcinomaBharathi Muthusamy, Kira Raskina, Katherine T Lofgren, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2014
Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to AlectinibSai-Hong Ignatius Ou, Samuel J Klempner, Joel R Greenbowe, et al.
Pageof 13

Showing results (21-30 of 130) with videos related to

Sort By:
Pageof 13
Lung Cancer (Amsterdam, Netherlands)|December 30, 2023
Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinomaLaura Burns, Hanna Tukachinsky, Kira Raskina, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutationSamuel J Klempner, Kyle Gowen, Thomas K Lee, et al.
Head & Neck|December 23, 2016
Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literatureLauren M Thorpe, Alexa B Schrock, Rachel L Erlich, et al.
JCO Precision Oncology|October 31, 2022
APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine TherapySarah Sammons, Kira Raskina, Natalie Danziger, et al.
The Oncologist|October 4, 2019
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current EvidenceSamuel J Klempner, David Fabrizio, Shalmali Bane, et al.
Lung Cancer (Amsterdam, Netherlands)|January 10, 2025
Genomic analysis of comprehensive next generation sequencing data to explore the criteria for MET amplification as an actionable biomarker in NSCLCDavid Chun Cheong Tsui, Jessica K Lee, Candice Francheska B Tambaoan, et al.
The Oncologist|January 27, 2019
Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior TestingLise Boussemart, Annie Nelson, Michael Wong, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinibSai-Hong Ignatius Ou, Jean Cui, Alexa B Schrock, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2022
Quantifying the Value of Multigene Testing in Resected Early Stage Lung AdenocarcinomaBharathi Muthusamy, Kira Raskina, Katherine T Lofgren, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2014
Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to AlectinibSai-Hong Ignatius Ou, Samuel J Klempner, Joel R Greenbowe, et al.
Pageof 13